Skip to main content
All lobbying filings

SUMMIT HEALTH CARE CONSULTING

SUMMIT HEALTH CARE CONSULTING filed a Q1 report for AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY on May 11, 2026, reporting $30,000 in lobbying income.

Lobbying for AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY · Health care trade association

All filings by SUMMIT HEALTH CARE CONSULTING · Everything AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted May 11, 2026
Income
$30,000
What the client paid this registrant for the period.
Client based in
Illinois

Official filing document

 Lobbyists on this filing 1
  • CAMILLE BONTA
    Previously held: Legislative Correspondent, U.S. Senator John Glenn

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Oppose Centers for Medicare and Medicaid Services' (CMS) proposal to implement an efficiency adjustment to Medicare Physician Fee Schedule payments. Support the Efficiency Adjustment Delay Act (H.R. 7520), which would stop the application of an efficiency adjustment until at least January 1, 2030. Oppose the CMS practice expense site differential proposal (no specific legislation) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation) Support the Improving Seniors Timely Access to Care Act (S. 1816, H.R. 3514) to codify CMS prior authorization regulations for MA plans and require greater transparency of prior authorization processes

Oppose the Patients Deserve Price Tags Act (S. 2355), specifically Section 5.

 Bills named in this filing 4
  • H.R. 7520
    Efficiency Adjustment Delay Act
  • S. 1816
    Improving Seniors’ Timely Access to Care Act of 2025
  • H.R. 3514
    Improving Seniors’ Timely Access to Care Act of 2025
  • S. 2355
    Patients Deserve Price Tags Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem